✦ LIBER ✦

High dose cyclophosphamide, etoposide and carmustine and peripheral stem cell transplantation for patients with relapsed hodgkin disease and bone marrow abnormalities

✍ Scribed by Anne Kessinger; Julie M. Vose; Philip J. Bierman; James O. Armitage

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Augmented high dose cyclophosphamide, et

✍ J.E. Schwartz; M.J. Robertson; K.G. Cornetta; L.D. Cripe; R.P. Nelson; C.T. Yian 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 76 KB

High-dose mitoxantrone and etoposide con

✍ S.H. Lim; T.P. Baglin; D. J. Flavell; S. U. Flavell; J. Z. Wimperis; R. E. Marcu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 431 KB

High-Dose Carmustine, Etoposide, and Cyc

✍ Lisa Y. Law; Sandra J. Horning; Ruby M. Wong; Laura J. Johnston; Ginna G. Laport 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 178 KB

High dose melphalan, BCNU and etoposide

✍ Zulian, GB; Selby, P; Milan, S; Nandi, A; Gore, M; Forgeson, G; Perren, TJ; McEl 📂 Article 📅 1989 🏛 Nature Publishing Group 🌐 English ⚖ 880 KB

Long-term Outcome of Hodgkin Disease Pat

✍ Navin Wadehra; Sherif Farag; Brian Bolwell; Patrick Elder; Sam Penza; Matt Kalay 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 180 KB

High-dose chemotherapy and autologous bo

✍ Harding, M.; Selby, P.; Gore, M.; Perren, T.; Treleavan, J.; Mansi, J.; Zulian, 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 616 KB